What is Microvisk?
Founded in 2004 and headquartered in Oxford, UK, Microvisk Technologies is a specialized developer of advanced medical devices focused on anticoagulation monitoring. The company distinguishes itself through the application of patented Micro Electro Mechanical Sensors (MEMS) technology, which facilitates high-precision testing for patients requiring PT/INR monitoring. By enabling both at-home and point-of-care diagnostic solutions, Microvisk addresses a critical need for efficient, accurate, and accessible patient care. As an ISO 13485:2016 accredited entity, the firm maintains rigorous quality standards, positioning itself as a key player in the intersection of biotechnology and consumer-facing health diagnostics.
How much funding has Microvisk raised?
Microvisk has raised a total of $22.9M across 3 funding rounds:
Series A
$3.9M
Series B
$9.5M
Series C
$9.5M
Series A (2010): $3.9M with participation from Oxford Technology Management and Finance Wales
Series B (2011): $9.5M led by New Hill Management and Oxford Technology
Series C (2011): $9.5M, investors not publicly disclosed
Key Investors in Microvisk
Oxford Technology Management
Oxford Technology specializes in managing SEIS and EIS funds that provide private investors with access to high-growth technology startup opportunities, primarily in the Oxford area.
Finance Wales
The Development Bank of Wales provides sustainable and effective business finance solutions, offering equity and loan support to fuel economic growth and innovation.
New Hill Management
New Hill Management is a private investment firm focused on identifying and supporting high-potential ventures within the technology and healthcare sectors.
What's next for Microvisk?
With the successful completion of its latest funding cycle, Microvisk is well-positioned to accelerate the commercialization of its CoagMax PT/INR System. The strategic allocation of this capital will likely focus on expanding market penetration, enhancing manufacturing scalability, and potentially diversifying its diagnostic portfolio. As the healthcare industry shifts toward decentralized testing models, Microvisk's MEMS-based platform provides a competitive advantage that could facilitate broader adoption among healthcare providers and patients alike. Future growth will depend on the company's ability to navigate regulatory landscapes while maintaining the high performance standards that have defined its development to date.
See full Microvisk company page
